Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Botulism mortality in the USA, 1975-2009.

Jackson KA, Mahon BE, Copeland J, Fagan RP.

Botulinum J. 2015;3(1):6-17. doi: 10.1504/TBJ.2015.078132. Epub 2016 Aug 4.

2.

Diversity of Group I and II Clostridium botulinum Strains from France Including Recently Identified Subtypes.

Mazuet C, Legeay C, Sautereau J, Ma L, Bouchier C, Bouvet P, Popoff MR.

Genome Biol Evol. 2016 Jun 13;8(6):1643-60. doi: 10.1093/gbe/evw101.

3.

Foodborne botulism in Canada, 1985-2005.

Leclair D, Fung J, Isaac-Renton JL, Proulx JF, May-Hadford J, Ellis A, Ashton E, Bekal S, Farber JM, Blanchfield B, Austin JW.

Emerg Infect Dis. 2013 Jun;19(6):961-8. doi: 10.3201/eid1906.120873.

4.

Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.

Šilhár P, Silvaggi NR, Pellett S, Čapková K, Johnson EA, Allen KN, Janda KD.

Bioorg Med Chem. 2013 Mar 1;21(5):1344-8. doi: 10.1016/j.bmc.2012.12.001. Epub 2012 Dec 20.

5.

Asymmetric type F botulism with cranial nerve demyelination.

Filozov A, Kattan JA, Jitendranath L, Smith CG, Lúquez C, Phan QN, Fagan RP.

Emerg Infect Dis. 2012 Jan;18(1):102-4. doi: 10.3201/eid1801.110471.

6.

Bioterrorism: preparing the plastic surgeon.

Chopra K, Conde-Green A, Folstein MK, Knepp EK, Christy MR, Singh DP.

Eplasty. 2011;11:e47. Epub 2011 Nov 23.

7.

Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.

Capek P, Zhang Y, Barlow DJ, Houseknecht KL, Smith GR, Dickerson TJ.

ACS Chem Neurosci. 2011 Jun 15;2(6):288-293.

8.

Botulinum toxin: bioweapon & magic drug.

Dhaked RK, Singh MK, Singh P, Gupta P.

Indian J Med Res. 2010 Nov;132:489-503. Review.

9.

Wound botulism in injection drug users: time to antitoxin correlates with intensive care unit length of stay.

Offerman SR, Schaefer M, Thundiyil JG, Cook MD, Holmes JF.

West J Emerg Med. 2009 Nov;10(4):251-6.

10.

Laboratory diagnostics of botulism.

Lindström M, Korkeala H.

Clin Microbiol Rev. 2006 Apr;19(2):298-314. Review.

11.

Acute neuromuscular respiratory paralysis.

Hughes RA, Bihari D.

J Neurol Neurosurg Psychiatry. 1993 Apr;56(4):334-43. Review. No abstract available.

12.

Botulinum toxin. From poison to medicine.

Davis LE.

West J Med. 1993 Jan;158(1):25-9. Review.

13.

Cloning of a DNA sequence unique to Clostridium botulinum group I by selective hybridization.

McKinney MW, Levett PN, Haylock RW.

J Clin Microbiol. 1993 Jul;31(7):1845-9.

14.

Localised autonomic failure due to botulinum toxin injection.

Bushara KO.

J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):105. No abstract available.

15.
16.

Botulism: a potentially common problem.

Shneerson JM.

Thorax. 1989 Nov;44(11):901-2. Review. No abstract available.

17.

Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult.

McCroskey LM, Hatheway CL, Woodruff BA, Greenberg JA, Jurgenson P.

J Clin Microbiol. 1991 Nov;29(11):2618-20.

18.

Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Schantz EJ, Johnson EA.

Microbiol Rev. 1992 Mar;56(1):80-99. Review.

Supplemental Content

Support Center